QL1203 + mFOLFOX6

**QL1203 + mFOLFOX6** is a combination therapy consisting of QL1203 and the mFOLFOX6 chemotherapy regimen. QL1203 is a biosimilar of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis, developed for cancer therapy. mFOLFOX6 is a standardized chemotherapy regimen comprising oxaliplatin (a platinum-based DNA crosslinking agent), leucovorin (folinic acid, enhances the effect of 5-fluorouracil), and 5-fluorouracil (an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis). The combination is primarily used in the treatment of colorectal and other gastrointestinal cancers, with QL1203 substituting for innovator bevacizumab to target tumor vasculature and inhibit growth, while mFOLFOX6 exerts cytotoxic effects on tumor cells through DNA damage and inhibition of cell proliferation[1][2][3][4][5].